SCHEMBL10095401

SCHEMBL10095401

CCn1c(C#Cc2ccc(Cl)cc2)c(C#N)c2ccc(O)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
SRC P12931 1/20 0.34
AR P10275 1/20 0.34
GRM4 Q14833 1/20 0.33
POLB P06746 1/20 0.33
ADRB2 P07550 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
S1PR1 P21453 1/20 0.32
PTGES O14684 1/20 0.32
ALOX5 P09917 1/20 0.32
CHEK1 O14757 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881494 0.88 APP (0.41) HTTKDM4EMEN1ALDH1A1LMNA
SCHEMBL10095395 0.88 L3MBTL1 (0.46) HTTKDM4EMEN1ALDH1A1LMNA
SCHEMBL10191034 0.86 ESR1 (0.39) HTTKDM4EMEN1ALDH1A1LMNA
SCHEMBL10095426 0.86 APP (0.46) HTTKDM4EMEN1ALDH1A1LMNA
SCHEMBL10095394 0.85 KDM4E (0.37) HTTKDM4EMEN1ALDH1A1LMNA
SCHEMBL2881493 0.84 PARP10 (0.37) HTTKDM4EMEN1ALDH1A1LMNA
SCHEMBL10095360 0.84 KDM4E (0.43) HTTKDM4EMEN1ALDH1A1LMNA
SCHEMBL13152789 0.83 GRM4 (0.34) HTTKDM4ELMNAGRM4POLB
SCHEMBL10095424 0.83 MEN1 (0.45) HTTKDM4EMEN1ALDH1A1MAPT
SCHEMBL10095382 0.82 RORC (0.45) HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927576-B2 HCV inhibitor and therapeutic agent combinations PTC Therpeutics, Inc. (US) 2015-01-06 US disclosed
US-8927576-B2 HCV inhibitor and therapeutic agent combinations PTC Therpeutics, Inc. (US) 2015-01-06 US disclosed
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations PTC THERAPEUTICS, INC. (US) 2012-02-02 US disclosed
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-8013006-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-09-06 US disclosed
US-7868037-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-01-11 US disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus EIF2AK2, INMT, IDO1 HTT 1585/4885KDM4E 433/4885MEN1 4550/4885
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS HTT 3355/4885KDM4E 3703/4885MEN1 4815/4885
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations HAVCR2, SERPINB1, ENPEP HTT 4273/4885KDM4E 4208/4885MEN1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.